• Gordon W Moe, Justin A Ezekowitz, Eileen O'Meara, Serge Lepage, Jonathan G Howlett, Steve Fremes, Abdul Al-Hesayen, George A Heckman, Howard Abrams, Anique Ducharme, Estrellita Estrella-Holder, Adam Grzeslo, Karen Harkness, Sheri L Koshman, Michael McDonald, Robert McKelvie, Miroslaw Rajda, Vivek Rao, Elizabeth Swiggum, Sean Virani, Shelley Zieroth, J Malcolm O Arnold, Tom Ashton, Michel D'Astous, Michael Chan, Sabe De, Paul Dorian, Nadia Giannetti, Haissam Haddad, Debra L Isaac, Simon Kouz, Marie-Hélène Leblanc, Peter Liu, Heather J Ross, Bruce Sussex, Michel White, and Canadian Cardiovascular Society.
• St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. Electronic address: moeg@smh.ca.
• Can J Cardiol. 2015 Jan 1; 31 (1): 3-16.

AbstractThe 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Update provides discussion on the management recommendations on 3 focused areas: (1) anemia; (2) biomarkers, especially natriuretic peptides; and (3) clinical trials that might change practice in the management of patients with heart failure. First, all patients with heart failure and anemia should be investigated for reversible causes of anemia. Second, patients with chronic stable heart failure should undergo natriuretic peptide testing. Third, considerations should be given to treat selected patients with heart failure and preserved systolic function with a mineralocorticoid receptor antagonist and to treat patients with heart failure and reduced ejection fraction with an angiotensin receptor/neprilysin inhibitor, when the drug is approved. As with updates in previous years, the topics were chosen in response to stakeholder feedback. The 2014 Update includes recommendations, values and preferences, and practical tips to assist the clinicians and health care workers to best manage patients with heart failure.Copyright © 2015 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

23 keywords...

hide…